Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-18
1999-06-01
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3140
Patent
active
059088575
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an agent for the treatment of infections, which is effective against virus infections, fungal infections, etc.
BACKGROUND ART
It is said that the infections have drastically changed in recent years. The classical infections have become latent, while infections that are difficult to treat and occur depending on the resistance of a patient to infections are increasing. Such infections occurring depending on the state of a patient are called opportunistic infections. Typical pathogens for opportunistic infections (herpes simplex virus type I) and their diseases are shown in Table 1. Many of the diseases are serious although they are caused by the same kind of pathogen.
TABLE 1 ______________________________________
infection under decreased
first infection
relapse infection-protective ability
______________________________________
stomatitis lip herpes herpes eczema
corneal herpes
generalized infection
adult encephalitis
______________________________________
The opportunistic infections refer to the state in which infections have been induced by pathogens of usually little pathogenity because the infection-protective ability of a patient is decreased for some reasons (increased susceptibility to infections). Hence, an agent having a recovery effect of infection-protective ability and an antimicrobial agent effective against pathogens are used to treat the opportunistic infections. In particular, the agent having a recovery effect of infection-protective ability is regarded as indispensable for essential treatment of the opportunistic infections.
However, the opportunistic infections show similar clinical symptoms although many are caused by a plurality of pathogens, and from the clinical symptoms, it is difficult to identify the pathogen, so it is also difficult to select a suitable antimicrobial agent for use in the opportunistic infections. Even if a suitable antimicrobial agent can be selected, substantial treatment of the opportunistic infections would not be achieved until the resistance of the patient is recovered. However, there are not a few cases where the lowered general conditions of the patient permit such an agent having a recovery effect of infection-protective ability to adversely induce a decrease in the infection-protective ability of the patient. At present, there is no agent that can be administered with confidence to treat or prevent the opportunistic infections.
Aconite tuber is tuberous roots of Aconitum carmichaeli of the family Ranunculaceae or other plants of the same genus, and it has been used for a long time as cardiotonic, analgesic, antiphlogistic, etc.
Aconite-alkaloids are aconite tuber-derived alkaloids known to have efficacy as analgesic, antiphlogistic, etc., and typical examples are benzoylmesaconine, benzoylaconine, benzoylhypaconine, 14-anisoylaconine, neoline, ignavine, mesaconine, hypaconine, 16-epi-pyromesaconitine, 16-epi-pyraconitine, 15-.alpha.-hydroxyneoline and ajaconine.
Rhizomes of Zingiber officinale Roscoe of the family Zingiberaceae have, for a long time, been used as ginger in medical formulation regarded as peptic, anti-emetic or analgesic, or in other medical formulation. In addition, gingerol as a component of ginger is known to have efficacy as antipyretic, analgesic, etc.
However, aconite tuber or an extract thereof or aconite-alkaloids or derivatives thereof, or ginger, dried ginger or an extract thereof, or gingerol or analogues thereof have never been used to treat infections such as virus infections, fungal infections, opportunistic infections, etc.
DISCLOSURE OF INVENTION
The object of the present invention is to provide an agent for the treatment of infections which has significant recovery effect of infection-protective ability.
The present inventors searched for a pharmaceutical preparation to improve the infection-protective ability of a patient that is decreased for some reasons (increased susceptibility to infections), and the present inventors found that aconite-alkaloids,
REFERENCES:
Alarcon et al, 1985, 102 CA:39536d.
Abidou et al 1967 67CA:106183k.
C. Atal, et al., "Immunomodulating Agents of Plant Origin. I: Preliminary Screening," Journal of Ethnopharmacology, 18 (1986); pp. 133-141.
V. Merck, et al., "Untersuchungen uber den Einsatz Homoopathischer Arzneimittel sur Behandlung akuter Mastitiden beim Rind," Berl Munch Tierarztl Wochenschr, vol. 102, No. 8, 1989; pp. 266-272.
V. Wagner, et al., "Die Beeinflussung der Phagozytosefahigkeit von Granulozyten durch homoopatische Arzneipraparate," Arzneim Forsch/Drug Res, vol. 36, No. 9, 1986; pp. 1421-1425.
R. Pollard, et al., "Effect of Benzoylmesaconine on Candida albicans Infection in Mice with Acquired Immunodeficiency Syndrome," U.S. Nat. Lib. of Med., US 31563;95920156, Feb. 2, 1995 (Abstract).
Suzuki Fujio
Travers Russell
LandOfFree
Agent for the treatment of infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for the treatment of infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for the treatment of infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-955155